SR 26831Alternative Names: SR 27899
Latest Information Update: 06 Aug 2002
At a glance
- Originator Sanofi-Synthelabo
- Class Antirheumatics
- Mechanism of Action Leucocyte elastase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 30 Aug 1999 Sanofi has merged with Synthélabo to form Sanofi-Synthélabo